We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Jerini Signs Collaboration Agreement with Baxter to Develop Peptide for Use in Therapeutic Protein Purification
News

Jerini Signs Collaboration Agreement with Baxter to Develop Peptide for Use in Therapeutic Protein Purification

Jerini Signs Collaboration Agreement with Baxter to Develop Peptide for Use in Therapeutic Protein Purification
News

Jerini Signs Collaboration Agreement with Baxter to Develop Peptide for Use in Therapeutic Protein Purification

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Jerini Signs Collaboration Agreement with Baxter to Develop Peptide for Use in Therapeutic Protein Purification"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Jerini AG has announced the signing of a research collaboration agreement with Baxter AG to develop a novel synthetic molecule for use in affinity purification of a therapeutic protein.

Under the terms of the agreement, Jerini will use its Peptides-to-Drugs (P2D) technology platform to identify and develop a specific binding molecule for protein purification, which potentially offers key advantages over conventional antibody-assisted protein purification.

"We are very pleased to announce our fourth collaboration agreement with Baxter. Jerini's proprietary P2D technology platform offers a unique and highly effective approach in the development of novel peptidomimetics or small molecules with applications in protein purification as well as drug development," said Jens Schneider-Mergener, Chief Executive Officer at Jerini.

Under the terms of the agreement, Jerini will receive an upfront payment and full time equivalents (FTE) funding along with potential milestone payments for the achievement of discovery, preclinical, and clinical goals and royalties on eventual product sales.

Advertisement